1. Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249. https://doi.org/10.3322/caac.21660 (2021).
2. Wang, Y. et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: A systematic review and meta-analysis. JAMA Oncol. 5(7), 1008–1019. https://doi.org/10.1001/jamaoncol.2019.0393 (2019).
3. Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., Sarker, D., Verset, G., Chan, S. L., Knox, J., Daniele, B., Webber, A. L., Ebbinghaus, S. W., Ma, J., Siegel, A. B., Cheng, A. L., Kudo, M. & KEYNOTE-224 Investigators. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial. Lancet Oncol. 19(7):940–952 (2018). Erratum in: Lancet Oncol. 19(9):e440 (2018).
4. Yau, T., Kang, Y. K., Kim, T. Y., El-Khoueiry, A. B., Santoro, A., Sangro, B., Melero, I., Kudo, M., Hou, M. M., Matilla, A., Tovoli, F., Knox, J. J., Ruth He, A., El-Rayes, B. F., Acosta-Rivera, M., Lim, H. Y., Neely, J., Shen, Y., Wisniewski, T., Anderson, J. & Hsu, C. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: The CheckMate 040 randomized clinical trial. JAMA Oncol. 6(11):e204564. https://doi.org/10.1001/jamaoncol.2020.4564 (2020). Erratum in: JAMA Oncol. 7(1):140 (2021).
5. Lee, M. S., Ryoo, B. Y., Hsu, C. H., Numata, K., Stein, S., Verret, W., Hack, S. P., Spahn, J., Liu, B., Abdullah, H., Wang, Y., He, A. R., Lee, K. H. & GO30140 Investigators. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): An open-label, multicentre, phase 1b study. Lancet Oncol. 21(6):808–820 (2020). Erratum in: Lancet Oncol. 21(7):e341 (2020).